【摘要】 目的 探讨血液透析对缬沙坦血药浓度的影响。方法 收集2018年1月至2022年1月于北京中医药大学厦门医院门诊就诊及住院的55例血液透析患者相关资料，受试者在血液透析前6 h服用缬沙坦胶囊80 mg,采集透析开始时及透析结束时透析器中静脉血，采用高效液相色谱法测定血药浓度。结果 缬沙坦低、中、高浓度的回收率分别为(100.75±1.36)%、(103.12±1.02)%、(101.68±2.37)%,相对标准偏差分别为1.35%、0.99%、2.33%。透析后缬沙坦血药浓度(0.47μg/mL)低于透析前(0.67μg/mL),差异有统计学意义(P<0.01)。患者年龄、血浆白蛋白、尿素氮、血肌酐与血药浓度均无相关性(P>0.01)。结论 缬沙坦在血液透析后血药浓度呈下降趋势。更多还原

【Abstract】 Objective To investigate the effect of hemodialysis on plasma concentration of valsartan.Methods The relevant data of 55 hemodialysis patients in Xiamen Hospital Affiliated to Beijing University of Traditional Chinese Medicine from January 2018 to January 2022 were collected.The subjects took 80 mg of valsartan capsule 6 hours before hemodialysis, and the venous blood was collected from the dialyzer at the beginning and end of dialysis, and the plasma concentration was determined by high performance liquid chromatography.Results The recovery rates of valsartan at low, medium and high concentrations were(100.75±1.36)%,(103.12±1.02)% and(101.68±2.37)%,respectively, and the relative standard deviation were 1.35 %,0.99 % and 2.33 %,respectively.The plasma concentration of valsartan after dialysis(0.47 μg/mL) was lower than that before dialysis(0.67 μg/mL),the difference was statistically significant(P<0.01).There was no correlation between age, plasma albumin, urea nitrogen, serum creatinine and plasma concentration(P>0.01).Conclusion The plasma concentration of valsartan shows a downward trend after hemodialysis.更多还原